Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma

Cancer Science

Volumn 99, Issue 4, 2008, Pages 726-732

  Oda, Yoshinao ^a   Kohashi, Kenichi ^a   Yamamoto, Hidetaka ^a   Tamiya, Sadafumi ^a   Kohno, Kimitoshi ^b   Kuwano, Michihiko ^c   Iwamoto, Yukihide ^a   Tajiri, Tatsuro ^a   Taguchi, Tomoaki ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c KURUME UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; EOSIN; GLYCOPROTEIN P; HEMATOXYLIN; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; Y BOX BINDING PROTEIN 1;

ADOLESCENT; ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA;

EID: 41349106177     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00748.x     Document Type: Article

References (35)

1. Kuwano M, Oda Y, Izumi H et al. The role of nuclear Y-box binding protein 1 as a global marker in drug resistance. Mol Cancer Ther 2004; 3: 1485-92.
2. Kohno K, Uchiumi T, Niida I et al. Transcription factors and drug resistance. Eur J Cancer 2005; 41: 2577-86.
3. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22: 7468-85.
4. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene 2003; 22: 7537-52.
5. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003; 22: 7340-58.
6. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EAC. Vaults: A ribonucleoprotein particle involved in drug resistance? Oncogene 2003; 22: 7458-67.
7. Bargou RC, Jurchott K, Wagener C et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 1997; 3: 447-50.
8. Oda Y, Sakamoto A, Shinohara N et al. Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. Clin Cancer Res 1998; 4: 2273-7.
9. Shibahara K, Sugio K, Osaki T et al. Nuclear expression of the Y-box binding protein, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 2001; 7: 3151-5.
10. Stein U, Bergmann S, Scheffer GL et al. YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 2005; 24: 3606-18.
11. Oda Y, Ohishi Y, Basaki Y et al. Prognostic implication of the nuclear localization of the Y-box-binding protein-1 and CXCR4 expression in ovarian cancer: Their correlation with activated Akt, LRP/MVP and P-glycoprotein expression. Cancer Sci 2007; 98: 1020-6.
12. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Eng J Med 1999; 341: 342-52.
13. Parham DM, Barr FG. Embryonal rhabdomyosarcoma. Alveolar rhabdomyosarcoma. In: Fletcher CDM, Unni KK, Mertens F, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press, 2002; 146-52.
14. Parham DM. Pathologic classification of rhabdomyosarcomas and correlations with molecular studies. Mod Pathol 2001; 14: 506-14.
15. Kelly KM, Womer RB, Sorensen PH, Xiong QB, Barr FG. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma. J Clin Oncol 1997; 15: 1831-6.
16. Lae M, Ahn EH, Mercado GE et al. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas. J Pathol 2007; 212: 143-51.
17. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW. Fusion of PAX3 to a member of the folkhead family of transcriptional factors in human alveolar rhabdomyosarcoma. Cancer Res 1993; 53: 5108-22.
18. Davis RJ, D'Cruz CM, Lovell MA et.al. Fusion of PAX7 to FKHR by variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res 1994; 54: 2869-72.
19. Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 1987; 329: 645-7.
20. Visser M, Sijmons C, Bras J et al. Allelotype of pediatric rhabdomyosarcoma. Oncogene 1997; 15: 1309-14.
21. Breneman JC, Lyden E, Pappo AS et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma Study-IV. J Clin Oncol 2003; 21: 78-84.
22. Crist WM, Anderson JR, Meza JL et al. Intergroup Rhabdomyosarcoma Study IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001; 19: 3091-102.
23. Komdeur R, Klunder J, van der Graaf WTA et al. Multidrug resistance proteins in rhabdomyosarcomas. Comparison between children and adults. Cancer 2003; 97: 1999-2005.
24. Lawrence W, Jr Anderson JR, Gehan EA, Maurer H. Pretreatment TMN staging of childhood rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Cancer 1997; 80: 1165-70.
25. Ohga T, Koike K, Ono M et al. Role of human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56: 4224-8.
26. Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y, Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol Rep 2000; 7: 859-66.
27. Sugawara I, Akiyama S, Scheper RJ, Itoyama S. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Lett 1997; 112: 23-31.
28. Baldini N, Scotlandi K, Barbanti-Brodano G et al. Expression of P-glycoprotein in high-grade osteosarcoma in relation to clinical outcome. N Engl J Med 1995; 333: 1380-5.
29. Endo K, Maehara Y, Ichiyoshi Y et al. Multidrug resistance-associated protein expression in clinical gastric carcinoma. Cancer 1996; 77: 1681-7.
30. Oda Y, Saito T, Tateishi N et al. ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer 2005; 114: 854-62.
31. Kuttesch JF, Parham DM, Luo X et al. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 1996; 14: 886-900.
32. Gallego S, Llort A, Parareda A, de Toledo JS. Expression of multidrug resistance-1 and multidrug resistance-associated protein genes in pediatric rhabdomyosarcoma. Oncol Rep 2003; 11: 179-83.
33. Klunder JW, Komdeur R, van der Graaf WTA et al. Expression of multidrug resistance-associated proteins in rhabdomyosarcomas before and after chemotherapy: The relationship between lung resistance-related protein (LRP) and differentiation. Hum Pathol 2003; 34: 150-5.
34. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr Drug Metab 2004; 5: 21-53.
35. Benderra Z, Faussat AM, Sayada L et al. MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 2005; 11: 7764-72.